Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial

Background: In metastatic breast cancer (MBC) patients, no biomarker predicting benefit to a bevacizumab-containing therapy has been established yet. MicroRNAs (miRNAs) are involved in angiogenesis and treatment resistance and therefore could be of predictive value. Methods: Profiling of 754 miRNAs...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Hackl, Hubert, Steiner, Markus, Monzo-Fuentes, Claudia, Melchardt, Thomas, Magnes, Teresa, Huemer, Florian, Westphal, Theresa, Hufnagl, Clemens, Hauser-Kronberger, Cornelia, Egle, Alexander, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355487/
https://www.ncbi.nlm.nih.gov/pubmed/32492882
http://dx.doi.org/10.3390/jcm9061663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355487/
https://www.ncbi.nlm.nih.gov/pubmed/32492882
http://dx.doi.org/10.3390/jcm9061663

Ejemplares similares